Investment Analysts’ Recent Ratings Changes for Shoulder Innovations (SI)

A number of research firms have changed their ratings and price targets for Shoulder Innovations (NYSE: SI):

• 8/10/2026 – Shoulder Innovations had its price target raised by UBS Group AG from $27.00 to $28.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Shoulder Innovations had its “overweight” rating reaffirmed by Piper Sandler. They now have a $25.00 price target on the stock, up from $19.00.
• 8/7/2026 – Shoulder Innovations had its price target raised by BTIG Research from $24.00 to $26.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Shoulder Innovations was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 7/28/2026 – Shoulder Innovations is now covered by UBS Group AG. They set a “buy” rating and a $27.00 price target on the stock.
• 6/29/2026 – Shoulder Innovations had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity

In other Shoulder Innovations news, major shareholder Healthcare Holding B.V. Gilde sold 2,095 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $22.60, for a total transaction of $47,347.00. Following the sale, the insider owned 2,212,207 shares of the company’s stock, valued at approximately $49,995,878.20. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Matthew Fraser Ahearn sold 4,144 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $18.84, for a total transaction of $78,072.96. Following the sale, the chief operating officer owned 269,176 shares of the company’s stock, valued at $5,071,275.84. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 188,275 shares of company stock worth $4,219,793 in the last three months. Corporate insiders own 29.00% of the company’s stock.

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.